All Mergers and acquisitions articles – Page 3
-
BusinessDowDupont names its three new separate businesses
Corteva Agriscience, Dow and DuPont will be what DowDuPont calls the three independent companies it will spin-off by June 2019
-
BusinessBMS stimulates cancer drug hopes with giant collaboration
Immunooncology pioneer will pay up to $3.6bn in hope Nektar drug will help non-responders
-
BusinessSanofi enters M&A bonanza
French drugmaker strengthens rare diseases portfolio with blood disorder purchases
-
BusinessCelgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
BusinessChemical industry roundup 2017
Economic and political pressure is encouraging industry to become more specialised as certain sectors consolidate
-
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
BusinessDuPont and Sumitomo link up for seed treatments
Firms will collaborate to develop and commercialise seed-applied technologies
-
BusinessBayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
BusinessChina moves in on US shale gas
Alaska and West Virginia have welcomed investment from Chinese entities to develop US shale resources
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
BusinessLilly and CureVac to collaborate on mRNA cancer vaccines
Deal could see CureVac net up to $1.8 billion in upfront and milestone payments
-
BusinessInvestor kills planned Huntsman–Clariant merger
Merger of equals abandoned after major Clariant investor said the deal would destroy stakeholder value
-
BusinessBASF to buy Bayer seeds and herbicides
€5.9bn sale will help satisfy competition regulators’ worries over Bayer–Monsanto merger
-
BusinessBASF to buy Solvay’s polyamide business
€1.6bn deal covers 2400 employees at sites in Europe, Asia and the Americas
-
BusinessTeva to sell off women’s health businesses for $1.4bn
Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts
-
BusinessTeva sells off contraceptive device in $1.1bn deal
CooperSurgical to acquire Paragard as Teva seeks to offload assets
-
BusinessHB Fuller targets growth with trio of deals
Adhesives manufacturer will buy one Brazilian and two US glue companies
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses